NTRK gene fusions in solid tumors and TRK inhibitors: a systematic review of case reports and case series
GM Iannantuono, S Riondino, S Sganga… - Journal of Personalized …, 2022 - mdpi.com
The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene
fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the …
fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the …
Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis
L Lemelle, D Guillemot, AL Hermann… - Expert Review of …, 2023 - Taylor & Francis
Background NTRK gene fusions have been identified in various tumors; some requiring
aggressive therapy and sometimes new TRK inhibitors (TRKi). We aimed to describe a …
aggressive therapy and sometimes new TRK inhibitors (TRKi). We aimed to describe a …
Genomics-Driven Precision Medicine in Pediatric Solid Tumors
P Suthapot, W Chiangjong, P Chaiyawat, P Choochuen… - Cancers, 2023 - mdpi.com
Simple Summary The detection of genomic aberrations in cancers has yielded a wealth of
information to discover oncogenic drivers or pathogenic variants that are relevant for the …
information to discover oncogenic drivers or pathogenic variants that are relevant for the …
Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study
R Mangum, J Reuther, K Sen Baksi… - Pediatric hematology …, 2023 - Taylor & Francis
The potential of circulating tumor DNA (ctDNA) analysis to serve as a real-time “liquid
biopsy” for children with central nervous system (CNS) and non-CNS solid tumors remains …
biopsy” for children with central nervous system (CNS) and non-CNS solid tumors remains …
Phase I Trial of GD2. CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors
FY Lin, A Stuckert, C Tat, M White, L Ruggieri… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE T cells modified with chimeric antigen receptors (CARTs) have demonstrated
efficacy for hematologic malignancies; however, benefit for patients with CNS tumors has …
efficacy for hematologic malignancies; however, benefit for patients with CNS tumors has …
Application of Drug Testing Platforms in Circulating Tumor Cells and Validation of a Patient-Derived Xenograft Mouse Model in Patient with Primary Intracranial …
ML Liang, TC Yeh, MH Huang, PS Wu, SP Wu… - Diagnostics, 2023 - mdpi.com
Primary intracranial ependymoma is a challenging tumor to treat despite the availability of
multidisciplinary therapeutic modalities, including surgical resection, radiotherapy, and …
multidisciplinary therapeutic modalities, including surgical resection, radiotherapy, and …
Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis
L Lemelle, D Guillemot, AL Hermann, A Gauthier… - papers.ssrn.com
Background: NTRK gene fusions have been identified in various tumor types associated
with variable outcomes, some requiring aggressive therapy. Recently new TRK inhibitors …
with variable outcomes, some requiring aggressive therapy. Recently new TRK inhibitors …